Ruxolitinib (Jakavi®) for Polycythaemia Vera. HTA ID: 20008

Assessment Status Assessment Process Complete
HTA ID 20008
Drug Ruxolitinib
Brand Jakavi®
Indication For the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.
Assessment Process
Rapid review commissioned 15/04/2015
Rapid review completed 28/05/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 13/04/2016
NCPE assessment completed 16/08/2016
NCPE assessment outcome Reimbursement Not Recommended

Technical Summary 2016

Resubmission of HTA

Assessment Process Assessment Process Complete
Resubmission of HTA commissioned by the HSE 04/03/2020
Pre-submission consultation with Applicant 09/03/2020
Full submission received from Applicant 16/09/2020
Preliminary review sent to Applicant 01/04/2021
NCPE assessment re-commenced 04/05/2021
Follow-up preliminary review sent to Applicant 19/05/2021
NCPE assessment re-commenced 26/05/2021
Factual accuracy sent to Applicant 28/06/2021
NCPE assessment re-commenced 09/07/2021
NCPE assessment completed 21/07/2021
NCPE assessment outcome The NCPE recommends that ruxolitinib (Jakavi®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.